Evidence map›Paper›PMID 32072135›Full record

ArticleNature metabolism2019

IDOL regulates systemic energy balance through control of neuronal VLDLR expression.

Stephen D Lee, Christina Priest, Mikael Bjursell, Jie Gao, Douglas V Arneson, In Sook Ahn, Graciel Diamante, J Edward van Veen, Megan G Massa, Anna C Calkin and 20 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Brap regulates liver morphology and hepatocyte turnover via modulation of the Hippo pathway.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 4 institutions in 4 countries.

Stephen D Lee *Department of Pathology and Laboratory Medicine, Department of Biological Chemistry, and Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-4663-9534
Christina Priest *Department of Pathology and Laboratory Medicine, Department of Biological Chemistry, and Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Mikael BjursellDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Jie GaoDepartment of Pathology and Laboratory Medicine, Department of Biological Chemistry, and Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Douglas V ArnesonDepartment of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA, USA.
In Sook AhnDepartment of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA, USA.
Graciel DiamanteDepartment of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA, USA.
J Edward van VeenDepartment of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA, USA.
Megan G MassaDepartment of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-8733-1547
Anna C CalkinDepartment of Pathology and Laboratory Medicine, Department of Biological Chemistry, and Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Jason KimDepartment of Pathology and Laboratory Medicine, Department of Biological Chemistry, and Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Harriet AndersénDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Prashant RajbhandariDepartment of Pathology and Laboratory Medicine, Department of Biological Chemistry, and Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Michelle PorrittDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Alba CarrerasDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Andrea AhnmarkResearch and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Frank SeeligerPathology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Ingela MaxvallResearch and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Pernilla EliassonResearch and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Magnus AlthageResearch and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Peter ÅkerbladResearch and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Daniel LindénResearch and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Tracy A ColeCentral Nervous System Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA.
Richard LeeCentral Nervous System Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA.
Helen BoydClinical Pharmacology and Safety Sciences, R&D, AstraZeneca; Cambridge Science Park, Cambridge, UK.
Mohammad Bohlooly-YDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Stephanie M CorreaDepartment of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA, USA.
Xia YangDepartment of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-3971-038X
Peter TontonozDepartment of Pathology and Laboratory Medicine, Department of Biological Chemistry, and Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. PTontonoz@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-1259-0477
Cynthia HongDepartment of Pathology and Laboratory Medicine, Department of Biological Chemistry, and Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USAstraZeneca (Sweden) · SEIonis Pharmaceuticals (United States) · USAstraZeneca (United Kingdom) · GB

Funding

Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Andrea L Hevener · 2003 to 2026
$40.4M
The Lipin Protein Family and Triglyceride Metabolism P01HL090553 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YOUNG, STEPHEN G. · 2008 to 2018
$23.3M
NUCLEAR RECEPTOR SIGNALING PATHWAYS IN ATHEROGENESISR01HL066088 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TONTONOZ, PETER J · 2001 to 2018
$5.4M
Training in Molecular ToxicologyT32ES015457 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALLARD, PATRICK, HANKINSON, OLIVER NMN · 2008 to 2025
$4.0M
Lipid-Responsive E3 ubiquitin ligases in cholesterol metabolism and atheroscierosisR01HL136618 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TONTONOZ, PETER J · 2018 to 2021
$2.4M
The Idol-ApoE receptor pathway in Alzheimer's diseaseR00AG054736 · NIA · OHIO STATE UNIVERSITY · PI GAO, JIE · 2019 to 2021
$747k
The Idol-ApoE receptor pathway in Alzheimer's diseaseK99AG054736 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GAO, JIE · 2017 to 2018
$193k
Novel LXR-Regulated E3 Ubiquitin Ligases in Lipid MetabolismF32HL123236 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PRIEST, CHRISTINA MARIE · 2014 to 2015
$113k
CIHRNHLBI NIH HHS F32 HL123236NHLBI NIH HHS P01 HL090553NHLBI NIH HHS R01 HL066088NHLBI NIH HHS R01 HL136618NIA NIH HHS K99 AG054736NIA NIH HHS R00 AG054736NIDDK NIH HHS P30 DK063491NIEHS NIH HHS T32 ES015457
6 · The paper itself

Abstract

Liver X receptors limit cellular lipid uptake by stimulating the transcription of Inducible Degrader of the LDL Receptor (IDOL), an E3 ubiquitin ligase that targets lipoprotein receptors for degradation. The function of IDOL in systemic metabolism is incompletely understood. Here we show that loss of IDOL in mice protects against the development of diet-induced obesity and metabolic dysfunction by altering food intake and thermogenesis. Unexpectedly, analysis of tissue-specific knockout mice revealed that IDOL affects energy balance, not through its actions in peripheral metabolic tissues (liver, adipose, endothelium, intestine, skeletal muscle), but by controlling lipoprotein receptor abundance in neurons. Single-cell RNA sequencing of the hypothalamus demonstrated that IDOL deletion altered gene expression linked to control of metabolism. Finally, we identify VLDLR rather than LDLR as the primary mediator of IDOL effects on energy balance. These studies identify a role for the neuronal IDOL-VLDLR pathway in metabolic homeostasis and diet-induced obesity.

Indexed as

AnimalsBlood GlucoseDietEnergy MetabolismHypothalamusInsulin ResistanceMiceMice, KnockoutNeuronsObesityReceptors, LDLUbiquitin-Protein LigasesBlood GlucoseMylip protein, mouseReceptors, LDLUbiquitin-Protein LigasesVLDL receptor

Identifiers

PMID32072135
PMCPMC7028310
OpenAlexW2981614517

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.